Wednesday, November 18, 2015
Print Current Session:
|
|
Wednesday
SESSION 31:
NATURAL HISTORY, MEDICAL TREATMENTS AND ANTI-ATHEROSCLEROTIC MEDICATIONS
Moderators:Keith D. Calligaro, MD / Hans-Henning Eckstein, MD, PhD
|
|
SESSION 31 SCHEDULE | |
6:45 AM - 6:50 AM | Is Metabolic Syndrome A Marker Of Adverse Outcomes After Vascular Procedures: What Can Be Done To Improve The Situation |
Presenter(s):Alan Dardik, MD, PhD | |
View Slides in PDF | |
6:51 AM - 6:56 AM | Cilostazol (Pletal) Is An Underutilized Medication In Vascular Patients: It Can Promote Patency And Decrease Amputations After Arterial Revascularizations: What Is Optimal Timing And Dosing For Its Use |
Presenter(s):Todd R. Vogel, MD, MPH | |
View Slides in PDF | |
6:57 AM - 7:03 AM | How Should Beta Blockers Be Used In Vascular Patients Undergoing Procedures: Use And Overuse Can Harm Patients And Their Use Should Not Be A Quality Metric |
Presenter(s):Michael C. Stoner, MD | |
View Slides in PDF | |
7:04 AM - 7:09 AM | How Do Patient Risk Factors And Antiplatelet Medications Influence Myocardial Ischemia And Infarction In Patients Undergoing Open Arterial Operations: What Can Be Done To Decrease These Adverse Events |
Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC | |
View Slides in PDF | |
7:10 AM - 7:15 AM | Smoking, Cholesterol, Obesity And BP: The Big 4 Modifiable Causes Of Vascular Disease: Fix Them And Live Forever: What Is Optimal Statin Usage |
Presenter(s):Richard Bulbulia, MA, MD, FRCS | |
View Slides in PDF | |
7:16 AM - 7:21 AM | What Is Happening With The AHA Cholesterol Guidelines: Should We Measure Serum Cholesterol: How Low Should The LDL Be Pushed To And Can It Get There |
Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC | |
View Slides in PDF | |
7:22 AM - 7:27 AM | Status Of Cholesterol Lowering Drug Zetia (Ezetimbe) And Its Combination With Statins (Vytorin): Do They Help To Prevent Cardiovascular Events More Than Statins Alone: Who Should Be On Them: The IMPROVE –IT Trial |
Presenter(s):Don Poldermans, MD | |
View Slides in PDF | |
7:28 AM - 7:33 AM | Status Of The New Cholesterol Lowering Drugs: The PCSK 9 Inhibitors (Evolucumab [Amgen] And Alirocumab [Sanofi]): Do They Decrease Cardiovascular Events: How Are They Given; What Are Their Downsides; What Will Their Role Be And When Will They Be Available |
Presenter(s):Ron Waksman, MD | |
View Slides in PDF | |
7:34 AM - 7:39 AM | Statins And Dual Antiplatelet Drugs Reduce Amputations: What Is The Evidence |
Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
View Slides in PDF | |
7:40 AM - 7:48 AM | Panel Discussion |
END OF SESSION 31 | |
previous | next |